Ливмониплимаб

Rec. INN (наименование, зарегистрированное ВОЗ)

2412004-88-5

immunoglobulin G4-kappa, anti-[Homo sapiens LRRC32 (leucine rich repeat containing 32, transforming growth factor beta activator LRRC32, glycoprotein A repetitions predominant, GARP) / Homo sapiens TGFB1 (transforming growth factor beta1, TGF beta) complex], chimeric and humanized monoclonal antibody;
gamma4 heavy chain chimeric (1-452) [VH Vicpac/Homsap (Vicugna pacos IGHV1-1*01 (87.8%) - (IGHD) -IGHJ3*01 (100%)/Homo sapiens IGHV1-46*01 (85.7%) -(IGHD) -IGHJ4*01 (85.7%), CDR-IMGT [8.8.19] (26-33.51-58.97-115)) (1-126)-Homo sapiens IGHG4*01, G4v5 h P10 (CH1 (127-224), hinge 1-12 S10>P (234) (225-236), CH2 (237-346), CH3 (347-451), CHS K2>del (452)) (127-452)], (140-214')-disulfide with kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-39*01 (85.3%) -IGKJ1*01 (100%), CDR- IMGT [6.3.9] (27-32.50-52.89-97)) (1'-107') -Homo sapiens IGKC*01 (100%), Km3 A45.1 (153), V101 (191) (108'-214')]; dimer (232-232'':235-235'')-bisdisulfide, produced in Chinese hamster ovary (CHO) cells, glycoform alfa

Поделиться этой страницей